Plesner assists LEO Foundation and LEO Pharma in connection with EUR 450 million investment by Nordic Capital
23 March 2021
Plesner has advised the LEO Foundation and LEO Pharma in connection with Nordic Capital's EUR 450 million investment in LEO Pharma. The partnership of the LEO Foundation and Nordic Capital and the investment shall further strengthen and support LEO Pharma's position as a global leader in medical dermatology.
LEO Pharma is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in more than 130 countries.
The LEO Foundation is one of Denmark's largest commercial foundations and the controlling owner of LEO Pharma. Nordic Capital is an active, experienced and leading private equity investor with a strong Scandinavian heritage. Nordic Capital will invest EUR 450 million in LEO Pharma and partner up with the LEO Foundation to support the company's 2030 strategy to be a global leader in medical dermatology. The LEO Foundation will remain the company's majority shareholder and Nordic Capital will be an active minority shareholder.
Plesner is immensely proud to have assisted the LEO Foundation and LEO Pharma in connection with the transaction. The Plesner team was headed by Lars Bunch,Thomas Holst Laursen and Hans Hedegaard together with Morten Stig Ottesen, Sara Hanquist Johnsen and Nina Charlotte Vestergaard.
The transaction is subject to customary regulatory approvals and completion is expected to take place in the first half of 2021.
Read the press release from Leo Foundation
The LEO Foundation is one of Denmark's largest commercial foundations and the controlling owner of LEO Pharma. Nordic Capital is an active, experienced and leading private equity investor with a strong Scandinavian heritage. Nordic Capital will invest EUR 450 million in LEO Pharma and partner up with the LEO Foundation to support the company's 2030 strategy to be a global leader in medical dermatology. The LEO Foundation will remain the company's majority shareholder and Nordic Capital will be an active minority shareholder.
Plesner is immensely proud to have assisted the LEO Foundation and LEO Pharma in connection with the transaction. The Plesner team was headed by Lars Bunch,Thomas Holst Laursen and Hans Hedegaard together with Morten Stig Ottesen, Sara Hanquist Johnsen and Nina Charlotte Vestergaard.
The transaction is subject to customary regulatory approvals and completion is expected to take place in the first half of 2021.
Read the press release from Leo Foundation
